Cost-benefit analysis of general immunization against hepatitis A in Croatia

Croatian Medical Journal

Volumn 37, Issue 3, 1996, Pages 193-199

  Puntarić, Dinko ^a   Božikov, Jadranka ^b   Vodopija, Radovan ^a  

^a Zagreb Institute of Public Health   (Croatia)

^b UNIVERSITY OF ZAGREB   (Croatia)

Author keywords

Cost benefit analysis; Hepatitis A; Immunization

Indexed keywords

HEPATITIS A VACCINE;

AGE; ARTICLE; COMPUTER MODEL; COST BENEFIT ANALYSIS; ECONOMIC ASPECT; HEPATITIS A; HUMAN; IMMUNIZATION; PASSIVE IMMUNIZATION; VACCINATION; YUGOSLAVIA;

EID: 0029762080     PISSN: 03539504     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Cvjetanović B, Grab B, Uemura K. Dynamics of acute bacterial diseases. Epidemiological models and their application in public health. Bull World Health Organ 1978;56(suppl 1):1-143.
2. Bailey NTJ. The mathematical theory of epidemics. London: Griffin, 1957.
3. Deželić G, Božikov J. Development of computerized epidemiological models of infectious diseases. In: van Bemmel JH, Ball MJ, Wigertz O, editors. MEDINFO 83. Proceedings of the Fourth World Conference on Medical Informatics. Amsterdam, 1983. Amsterdam: North-Holland, 1983:1218-21.
4. Delimar N, Košiček M, Cvjetanović B. Epidemiološki modeli zaraznih oboljenja i njihova primjena. In: Borčić B, Aleraj B, editors. I. Kongres epidemiologa Jugoslavije. Zbornik radova. Zadar: Epidemiološka sekcija Zbora liječnika Hrvatske, 1987:158-9.
5. John V, Božikov J, Cvjetanović B, Benčić Z, Deželić D. Primjena metode modeliranja i kontinuirane simulacije za praćenje zaraznih bolesti u populaciji i odabir strategije za njihovo suzbijanje. In: Borčić B, Aleraj B, editors. I. Kongres epidemiologa Jugoslavije. Zbornik radova. Zadar: Epidemiološka sekcija Zbora liječnika Hrvatske, 1987:159-62.
6. Delimar N, Košiček M, Delimar D, Sivik T. Epidemiological model of hepatitis A. Period biol 1993;95: 409-14.
7. Evidencija prijavljenih slučajeva zaraznih bolesti od 1970. do 1991. godine na području Hrvatske. Zagreb: Hrvatski zavod za javno zdravstvo, 1992.
8. Puntarić D, Vodopija I, Baklaić Ž, Ljubičić M. Imunitet na HAV mlacrossed d signih dobnih skupina - osnova za pogram imunizacije. Liječ Vjesn 1995;117:167-72.
9. Republički zavod za statistiku. Popis stanovnika 1991. godine. Dokumentacija 881. Zagreb: Republički zavod za statistiku, 1992.
10. Statistički godišnjak SR Hrvatske 1965-1985. Zagreb: Republički zavod za statistiku SR Hrvatske, 1965-1985.
11. Ruiz-Gomez J, Bustamante-Calvillo ME. Hepatitis A antibodies: prevalence and persistence in a group of Mexican children. Am J Epidemiol 1985;121:116-9.
12. Kilpatrick ME, Escamilla J. Hepatitis A in Peru. Am J Epidemiol 1986;124:111-3.
13. Košutić Z. Virusni hepatitis, Hepatitis virosa. In: Mihaljević F, Fališevac J, Bezjak B, Mravunac B. Specijalna klinička infektologija. Zagreb: JUMENA, 1988: 341-56.
14. Hrabar A. Specijalna epidemiologija. Zagreb: Viša škola za medicinske sestre i zdravstvene tehničare, 1981: 48-73.
15. Palmović D. Hepatitis A - rezultati obrade 3111 hospitaliziranih bolesnika. Liječ Vjesn 1989;111:194-7.
16. Papaevangelou GJ. Epidemiology of hepatitis A and B. Infection 1987;15:221-7.
17. Hrabar A, Borčić B. Neka obilježja epidemije infekcioznog hepatitisa u Hrvatskoj. Zdravstvene novine 1967;19:108-13.
18. Likat M. Hepatitis virusi. In: Karakašević B, Agolli B, Berger-Jekić O, Brudnjak Z, Derkos-Mikulić V, Drndarski K et al. Mikrobiologija i parazitologija. Beograd-Zagreb: Medicinska knjiga, 1989:1341-8.
19. Centers for Disesase Control. Hepatitis surveillance. Atlanta (GA), USA: Centers for Disesase Control, 1986;50:10-1.
20. Vernon AA, Schabel C, Francis D. A large outbreak of hepatitis A in a day-care center. Am J Epidemiol 1982;115:325-31.
21. Jelić O, Mihaljević I, Fišer-Herman M, Borčić B, Aleraj B. Dokazivanje antitijela u epidemijama hepatitisa A. Acta Med lugoslavica 1980;34:267-8.
22. Cornu C, Lamy ME, Geubel A, Galanti L. Persistence of immunoglobulin M antibody to hepatitis A virus and relapse of hepatitis A infection. Eur J Clin Microbiol 1984;3:45-6.
23. Shuvalova EP, Vinogradova EN, Karetny YV, Balayan MS. Protracted forms of viral hepatitis A in adolescents. Klin Med (Mosk) 1989;67:49-52.
24. Jacobson IM, Nath BJ, Dienstag JL. Relapsing viral hepatitis type A. J Med Virol 1985;16:163-9.
25. Flehmig B, Heinricy U. Hepatitis A vaccine. Lancet 1989;ii:114.
26. Flehmig B, Haage A, Pfisterer M. Immunogenicity of a hepatitis A virus vaccine. J Med Virol 1987;22:7-16.
27. Flehmig B, Heinricy U, Pfisterer M. Immunogenicity of killed hepatitis A vaccine in seronegative volunteers. Lancet 1989;i:1039-41.
28. Smith Kline Beecham Pharmaceuticals. "Havrix" - prescribing information. Brussels: Smith Kline Beecham Pharmaceuticals, 1992.
29. Schweiz Impfinstitut. HAV FB 02 - prescribing information. Bern, Switzerland: Schweiz Impfinstitut, 1992.
30. World Health Organization. Weekly Epidemiological Report. Geneva: WHO, 1992;35:261-3.
31. Peetermans J. Production, quality control and characterisation of an inactivated hepatitis A vaccine. Vaccine 1992;10(suppl 1):99-101.
32. Kane MA. Perspective on the control of hepatitis A by vaccination. Vaccine 1992;10(suppl 1):93-6.
33. Margolis HS, Shapiro CN. Who should receive hepatitis A vaccine? Consideration for the development of an immunization strategy. Vaccine 1992;10(suppl 1):85-7.
34. Andre FE, D'Hondt E, Delem A, Safary A. Clinical assessment of safety and efficacy of an inactivated hepatitis A vaccine: rationale and summary of findings. Vaccine 1992;10(suppl 1):160-8.
35. Aarhaug P. Field evaluation of a hepatitis A vaccine in a Norwegian contingent to the United Nations Interim Force in Lebanon. Vaccine 1992;10(suppl 1):156-8.
36. Riedemann S, Reinhardt G, Frosner GG Ibarra H, Moraleda L Hering V et al. Placebo-controlled efficacy study of hepatitis A vaccine in Valdivia, Chile. Vaccine 1992;10(suppl 1):152-5.
37. Jilg W, Bittner R, Bock HL, Clemens R, Schatzl H, Schmidt M, et al. Vaccination against hepatitis A: comparation of different short-term immunization schedules. Vaccine 1992;10(suppl 1):126-8.
38. Davidson M, Krugman S, Sandam LA. Inactivated hepatitis A vaccine: a safety and immunogenicity study in health professionals. Vaccine 1992;10(suppl 1):119-20.
39. Just M, Berger R, Dreschsler H, Brantschen S, Gluck R. A single vaccination with an inactivated hepatitis A liposome vaccine induces protective antibodies after only two weeks. Vaccine 1992;10(suppl 1):737-9.
40. Ellerbeck EF, Lewis JA, Nalin D, Gershman K, Miller WJ, Armstrong ME et al. Safety profile and immunogenicity of an inactivated vaccine derived from an attenuated strain of hepatitis A. Vaccine 1992;10(suppl 1):668-72.
41. Werzberger A, Mench B, Kuter B, Brown L, Lewis J, Sitrin R et al. A controlled trial of a formalin-inactivated hepatitis A vaccine in healthy children. N Engl J Med 1992;327:453-7.
42. Puntarić D. Imunitet na HAV mlacrossed d signih dobnih skupina - osnova za program imunizacije [doctoral dissertation]. Zagreb: Medicinski fakultet Sveučilišta u Zagrebu, 1994.
43. Egoz N. Cost-benefit of mass prophylaxis with immune serum globulin to control waterborne hepatitis A: a case study. Isr J Med Sci 1986;22:277-82.
44. Zakon o porezu na dohodak. Narodne novine 1995; 25:750-62.
45. Briem H, Weiland O, Fridriksson I, Berg R. Prevalence of antibody to hepatitis A in Iceland in relation to age, sex, and number of notified cases of hepatitis. Am J Epidemiol 1982;116:451-5.
46. Armigliato M, Bortolotti F, Bertaggia A, Carretta M, Meneghetti F, Noventa F et al. Epidemiology of hepatitis A in Northern Italy: a seven-year survey. Infection 1986;14:283-5.
47. Ikematsu H, Kashiwagi S, Hayashi J, Nomura H, Kajiyama W, Tani S et al. A seroepidemiologic study of hepatitis A virus infections: statistical analysis of two independent cross-sectional surveys in Okinawa, Japan. Am J Epidemiol 1987;126:50-4.
48. Marušić M, Kostović I. Attacks on Croatia's hospitals. Lancet 1991;338:1018.
49. Markeljević J, Lacković Z. The case of Croatian hospitals: is this the end of humanitarian rules? Medicine and War 1994;10:50-62.
50. Mao JS, Dong DX, Zhang HY, Chen NL, Huang HY et al. Primary study of attenuated live hepatitis A vaccine (H2 strain) in humans. J Infect Dis 1989;159:621-4.
51. Mao JS. Development of live attenuated hepatitis A vaccine (H2-strain). Vaccine 1990;8:523-4.